125 related articles for article (PubMed ID: 38917571)
1. Contractility assessment using aligned human iPSC-derived cardiomyocytes.
Satsuka A; Ribeiro AJS; Kawagishi H; Yanagida S; Hirata N; Yoshinaga T; Kurokawa J; Sugiyama A; Strauss DG; Kanda Y
J Pharmacol Toxicol Methods; 2024 Jun; 128():107530. PubMed ID: 38917571
[TBL] [Abstract][Full Text] [Related]
2. Speckle-Tracking Strain Analysis for Mapping Spatiotemporal Contractility of Induced Pluripotent Stem Cell (iPSC)-Derived Cardiomyocytes.
Izadifar M; Berecz T; Li B; Tang JKKY; Foldes G; Apati A; Nagy A
Curr Protoc; 2023 Sep; 3(9):e889. PubMed ID: 37747346
[TBL] [Abstract][Full Text] [Related]
3. Contractility assessment of human iPSC-derived cardiomyocytes by using a motion vector system and measuring cell impedance.
Satsuka A; Hayashi S; Yanagida S; Ono A; Kanda Y
J Pharmacol Toxicol Methods; 2022; 118():107227. PubMed ID: 36243255
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Changes in Morphology and Function of Human Induced Pluripotent Stem Cell Derived Cardiomyocytes (HiPSC-CMs) Cultured on an Aligned-Nanofiber Cardiac Patch.
Khan M; Xu Y; Hua S; Johnson J; Belevych A; Janssen PM; Gyorke S; Guan J; Angelos MG
PLoS One; 2015; 10(5):e0126338. PubMed ID: 25993466
[TBL] [Abstract][Full Text] [Related]
5. Contractility and Calcium Transient Maturation in the Human iPSC-Derived Cardiac Microfibers.
Strimaityte D; Tu C; Yanez A; Itzhaki I; Wu H; Wu JC; Yang H
ACS Appl Mater Interfaces; 2022 Aug; 14(31):35376-35388. PubMed ID: 35901275
[TBL] [Abstract][Full Text] [Related]
6. Development of appropriate fatty acid formulations to raise the contractility of constructed myocardial tissues.
Yoshida A; Sekine W; Homma J; Sekine H; Itoyama YY; Sasaki D; Matsuura K; Kobayashi E; Shimizu T
Regen Ther; 2022 Dec; 21():413-423. PubMed ID: 36248630
[TBL] [Abstract][Full Text] [Related]
7. Acute effects of cardiac contractility modulation on human induced pluripotent stem cell-derived cardiomyocytes.
Feaster TK; Casciola M; Narkar A; Blinova K
Physiol Rep; 2021 Nov; 9(21):e15085. PubMed ID: 34729935
[TBL] [Abstract][Full Text] [Related]
8. SarcTrack.
Toepfer CN; Sharma A; Cicconet M; Garfinkel AC; Mücke M; Neyazi M; Willcox JAL; Agarwal R; Schmid M; Rao J; Ewoldt J; Pourquié O; Chopra A; Chen CS; Seidman JG; Seidman CE
Circ Res; 2019 Apr; 124(8):1172-1183. PubMed ID: 30700234
[TBL] [Abstract][Full Text] [Related]
9. Matrigel Mattress: A Method for the Generation of Single Contracting Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
Feaster TK; Cadar AG; Wang L; Williams CH; Chun YW; Hempel JE; Bloodworth N; Merryman WD; Lim CC; Wu JC; Knollmann BC; Hong CC
Circ Res; 2015 Dec; 117(12):995-1000. PubMed ID: 26429802
[TBL] [Abstract][Full Text] [Related]
10. Scalable Biomimetic Coaxial Aligned Nanofiber Cardiac Patch: A Potential Model for "Clinical Trials in a Dish".
Kumar N; Sridharan D; Palaniappan A; Dougherty JA; Czirok A; Isai DG; Mergaye M; Angelos MG; Powell HM; Khan M
Front Bioeng Biotechnol; 2020; 8():567842. PubMed ID: 33042968
[TBL] [Abstract][Full Text] [Related]
11. [Cardiotoxicity risk assessment of anti-cancer drugs and future perspectives].
Yanagida S; Kawagishi H; Kanda Y
Nihon Yakurigaku Zasshi; 2024; 159(2):83-89. PubMed ID: 38432924
[TBL] [Abstract][Full Text] [Related]
12. Aligned human induced pluripotent stem cell-derived cardiac tissue improves contractile properties through promoting unidirectional and synchronous cardiomyocyte contraction.
Takada T; Sasaki D; Matsuura K; Miura K; Sakamoto S; Goto H; Ohya T; Iida T; Homma J; Shimizu T; Hagiwara N
Biomaterials; 2022 Feb; 281():121351. PubMed ID: 34979417
[TBL] [Abstract][Full Text] [Related]
13. Does Enhanced Structural Maturity of hiPSC-Cardiomyocytes Better for the Detection of Drug-Induced Cardiotoxicity?
Van de Sande D; Ghasemi M; Watters T; Burton F; Pham L; Altrocchi C; Gallacher DJ; Lu H; Smith G
Biomolecules; 2023 Apr; 13(4):. PubMed ID: 37189424
[TBL] [Abstract][Full Text] [Related]
14. Video-based assessment of drug-induced effects on contractile motion properties using human induced pluripotent stem cell-derived cardiomyocytes.
Okai Y; Matsune K; Yamanaka K; Matsui T; Pfeiffer Kaushik E; Harada K; Kohara H; Miyawaki A; Ozaki H; Wagoner M; Shinozawa T
J Pharmacol Toxicol Methods; 2020 Sep; 105():106893. PubMed ID: 32619502
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes.
Feaster TK; Casciola M; Narkar A; Blinova K
J Vis Exp; 2022 Dec; (190):. PubMed ID: 36591970
[TBL] [Abstract][Full Text] [Related]
16. Cardiotoxicity Assessment of Drugs Using Human iPS Cell-Derived Cardiomyocytes: Toward Proarrhythmic Risk and Cardio-Oncology.
Satsuka A; Kanda Y
Curr Pharm Biotechnol; 2020; 21(9):765-772. PubMed ID: 31264543
[TBL] [Abstract][Full Text] [Related]
17. Moving beyond the comprehensive in vitro proarrhythmia assay: Use of human-induced pluripotent stem cell-derived cardiomyocytes to assess contractile effects associated with drug-induced structural cardiotoxicity.
Yang X; Papoian T
J Appl Toxicol; 2018 Sep; 38(9):1166-1176. PubMed ID: 29484688
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneous filament network formation by myosin light chain isoforms effects on contractile energy output of single cardiomyocytes derived from human induced pluripotent stem cells.
Mizutani T; Furusawa K; Haga H; Kawabata K
Regen Ther; 2016 Mar; 3():90-96. PubMed ID: 31245478
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of cardiotoxicity assessment using calcium transient in human induced pluripotent stem cell-derived cardiomyocytes.
Watanabe H; Honda Y; Deguchi J; Yamada T; Bando K
J Toxicol Sci; 2017; 42(4):519-527. PubMed ID: 28717111
[TBL] [Abstract][Full Text] [Related]
20. Inducing positive inotropy in human iPSC-derived cardiac muscle by gene editing-based activation of the cardiac α-myosin heavy chain.
Bedada FB; Thompson BR; Mikkila JL; Chan SS; Choi SH; Toso EA; Kyba M; Metzger JM
Sci Rep; 2024 Feb; 14(1):3915. PubMed ID: 38365813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
